Free Trial
NASDAQ:BLUE

bluebird bio 9/27/2024 Earnings Report

bluebird bio EPS Results

Actual EPS
-$8.40
Consensus EPS
-$8.00
Beat/Miss
Missed by -$0.40
One Year Ago EPS
N/A

bluebird bio Revenue Results

Actual Revenue
$16.10 million
Expected Revenue
$16.09 million
Beat/Miss
Beat by +$10.00 thousand
YoY Revenue Growth
N/A

bluebird bio Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

bluebird bio's Q1 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

bluebird bio Earnings Headlines

Market Crash Warning: How to Protect Your Wealth Before August 12th
China tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alternative Assets reveals 3 urgent moves to protect your portfolio, plus the #1 asset class thriving during crises (hint: it’s not stocks or bonds).
See More bluebird bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bluebird bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bluebird bio and other key companies, straight to your email.

About bluebird bio

bluebird bio (NASDAQ:BLUE), a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

View bluebird bio Profile

More Earnings Resources from MarketBeat